Mankind Pharma on Monday said it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to initiate a Phase 1 clinical trial for a molecule under development for the treatment of multiple autoimmune disorders. The molecule is being developed for the treatment of multiple autoimmune disorders, including rheumatoid arthritis, ulcerative colitis, plaque psoriasis,…
Mankind Pharma Wins PETKIND Trademark Battle, Court Orders Journal Advertisement Within Two Months We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a “good” share of the market, Krishnakumar Vaidyanathan, executive director and chief operating…
New Delhi: Employees in pharma companies are likely to get an increment of 9.6% in 2025, a tad lower than last year but still exceeding the average pay hike of 8.8% projected for corporate India, according to a Deloitte study. New roles like regen medicine researcher (who investigates ways to repair or replace damaged tissues…